Ocular Pulse Amplitude And Choroidal Laser Doppler Flowmetry - Full Text View

Purpose

This study intends to investigate the relationship between choroidal blood flow and ocular pulse amplitude (OPA).

Condition

Healthy

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective

Official Title:	Relationship Between Ocular Pulse Amplitude And Choroidal Laser Doppler Flowmetry In Healthy Subjects

Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:

An association of OPA with the LDF pulsatility index [ Time Frame: 30 seconds ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

An association of OPA with the systemic blood pressure values [ Time Frame: 30 seconds ] [ Designated as safety issue: No ]
An association of OPA with mean intraocular pressure [ Time Frame: 30 seconds ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	18
Study Start Date:	January 2006
Estimated Study Completion Date:	April 2008
Estimated Primary Completion Date:	April 2008 (Final data collection date for primary outcome measure)

Detailed Description:

One eye is randomly selected in 18 healthy subjects. OPA is assessed with Dynamic Contour Tonometry. Submacular choroidal blood flow is measured with Laser Doppler Flowmetry. During both examinations the systemic blood pressure is continuously recorded with Finometer. An average systolic and diastolic LDF parameter flow during 30 seconds are determined and the pulsatility index is calculated according to the formula (LDFsys-LDFdia)/LDFdia. An association of OPA with the LDF pulsatility index, systemic blood pressure values and mean intraocular pressure will be analysed.

Eligibility

Ages Eligible for Study:	45 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

healthy subjects

Criteria

Inclusion Criteria:

Healthy subjects should present no history of ocular diseases, of current topical medication, or of drug or alcohol abuse. Furthermore, a best corrected visual acuity above 20/25 in both eyes, lack of pathological findings upon a slit-lamp examination and dilated direct fundoscopy, and an IOP < 21 mmHg in both eyes will be required.

Exclusion Criteria:

History of chronic or recurrent severe inflammatory eye disease such as scleritis or uveitis.
History of ocular trauma or intraocular surgery. History of infection or inflammation within the past 3 months.
History and clinical evidence for other retinal disease such as age-related degeneration, or diabetic retinopathy.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00409110

Contacts


Contact: Robert Katamay, MD	+41-61-58629	rkatamay@uhbs.ch

Locations


Switzerland, Basel-Stadt
	University Eye Clinic Basel	Recruiting
	Basel, Basel-Stadt, Switzerland, 4031
	Contact: Selim Orguel, MD +41-61-2658787 sorguel@uhbs.ch

Sponsors and Collaborators

University Hospital, Basel, Switzerland

Investigators


Study Director:	Selim Orguel, MD	University Eye Clinic Basel

More Information

Responsible Party:	University Hospital, Basel, Switzerland ( Selim Orgul )
Study ID Numbers:	082-KAR-2006-001
First Received:	December 7, 2006
Last Updated:	January 14, 2008
ClinicalTrials.gov Identifier:	NCT00409110
Health Authority:	Switzerland: Swissmedic

Keywords provided by University Hospital, Basel, Switzerland:

Ocular Pulse Amplitude

Dynamic Contour Tonometry

Pulsatility Index

Choroidal Laser Doppler Flowmetry

Finometer

Study placed in the following topic categories:

Healthy

ClinicalTrials.gov processed this record on September 05, 2008

Sponsored by:	University Hospital, Basel, Switzerland
Information provided by:	University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:	NCT00409110